Pfizer's Besponsa Receives FDA Approval for Treatment of Pediatric Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

On March 6 local time, the U.S. Food and Drug Administration (FDA) approved Pfizer's BESPONSA® (inotuzumab ozogamicin) for the treatment of pediatric patients aged 1 year and older with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL). (Interface)Original Link